Which statements about essential thrombocythemia are correct regarding the diagnostic platelet count threshold and treatment with hydroxyurea plus low‑dose aspirin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Essential Thrombocythemia: Diagnostic Criteria and Treatment

Statement (d) is correct: treatment consists of hydroxyurea and low-dose aspirin for high-risk patients with essential thrombocythemia. 1

Diagnostic Platelet Count Threshold

The provided answer options regarding diagnostic criteria are all incorrect based on current guidelines. The diagnosis of essential thrombocythemia requires sustained platelet elevation ≥450,000/mm³ according to WHO criteria, not the thresholds listed in options a, b, or c. 1 However, none of the answer choices accurately reflect this standard diagnostic criterion.

Treatment Approach for Essential Thrombocythemia

High-Risk Patients (Age ≥60 years and/or prior thrombosis)

The combination of hydroxyurea plus low-dose aspirin (81-100 mg daily) is the standard first-line treatment for high-risk essential thrombocythemia patients. 1

  • Hydroxyurea has proven efficacy in preventing thrombotic complications in randomized controlled trials, reducing thrombotic events from 24% to 3.6% in high-risk patients. 2
  • The target platelet count during treatment is <400 × 10⁹/L, not the diagnostic threshold. 1
  • Low-dose aspirin (81-100 mg daily) is used concurrently for thrombosis prevention, not high-dose aspirin >1,000 mg as suggested in option (e). 1

Hydroxyurea Dosing and Monitoring

  • Standard dosing is at least 2 g/day (or 2.5 g/day in patients >80 kg) for 3 months to assess response. 1, 3, 4
  • Treatment resistance is defined as platelet count >600 × 10⁹/L after 3 months of adequate hydroxyurea dosing. 1, 3
  • Monitor complete blood counts every 4-8 weeks once stabilized. 3

Critical Treatment Thresholds

Cytoreductive therapy is specifically indicated when:

  • Platelet count >1,500 × 10⁹/L (due to increased bleeding risk, not thrombotic risk). 5, 6, 7
  • Symptomatic or progressive splenomegaly develops. 1, 3
  • Microvascular symptoms (erythromelalgia, transient neurological attacks) occur. 5

Common Pitfall to Avoid

High-dose aspirin (>1,000 mg) is never recommended in essential thrombocythemia. The standard dose is 81-100 mg daily. 1 High-dose aspirin increases bleeding risk without additional thrombotic protection, particularly problematic when platelet counts exceed 1,500 × 10⁹/L. 5, 7

Mandatory Discontinuation Criteria

Stop hydroxyurea immediately if any of the following occur:

  • Absolute neutrophil count <1.0 × 10⁹/L 1, 3
  • Platelet count <100 × 10⁹/L 1, 3
  • Hemoglobin <10 g/dL 1, 3
  • Development of leg ulcers or severe mucocutaneous manifestations 1, 3

Second-Line Options for Hydroxyurea Resistance/Intolerance

  • Anagrelide is the recommended second-line therapy for essential thrombocythemia. 3
  • Interferon-alpha may be considered, particularly in younger patients (<40 years) or pregnant patients requiring cytoreductive therapy. 1, 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment of Thrombocytosis with Hydroxyurea

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Hydroxyurea Dosage Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

What is the standard treatment in essential thrombocythemia.

International journal of hematology, 2002

Research

Essential thrombocythemia: past and present.

Internal and emergency medicine, 2009

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.